• Quince posted fiscal 2025 net loss of $84 million, widening 48%.
• Operating loss edged up 1% to $58.1 million; revenue remained nil.
• R&D expense jumped 90% to $35.4 million, driven by ramp-up and continuation costs for Phase 3 NEAT clinical trial and OLE.
• Phase 3 NEAT trial of eDSP in A-T missed primary endpoint (p=0.0851) and key secondary endpoint (p=0.522), prompting the company to cease eDSP development and focus on strategic alternatives including a reverse merger.
• Quince ended 2025 with $17.8 million in cash, cash equivalents and short-term investments, projecting funding into Q2 2026, or into H2 2026 if June 2025 common warrants are exercised in full for cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-151364), on April 10, 2026, and is solely responsible for the information contained therein.